title: [Treatment of recurrent neovascular age-related macular degeneration with ranibizumab according to the PrONTO scheme].
abstract: BACKGROUND
  The goal of this retrospective study was to evaluate the development of visual acuity before and after recurrence treatment of neovascular age-related macular degeneration (AMD) in a university eye clinic with referring ophthalmologists.
  
  
  METHODS
  Data from patients with recurrent neovascular AMD who initially had been treated for neovascular AMD and followed by referring ophthalmologists were analyzed. An intravitreal recurrence treatment with ranibizumab using the same PrONTO scheme as used in the "upload" phase followed.
  
  
  RESULTS
  Mean best corrected visual acuity (BCVA) of all 100 patients included in the study was - 0.61 ± 0.33 LogMAR before treatment and improved to - 0.36 ± 0.24 LogMAR (p < 0.001) after "upload" therapy. Mean central retinal thickness (CRT) was 291.5 ± 85.3 μm before treatment and decreased to 200.1 ± 63.7 μm after "upload" therapy (p < 0.001). At the time of recurrence the mean BCVA was - 0.63 ± 0.33 LogMAR and improved significantly to - 0.52 ± 0.28 LogMAR (p < 0.001) after recurrence treatment. At the time of recurrence the mean CRT was 281.2 ± 94.4 μm and decreased significantly to 202.7 ± 59.9 μm after recurrence treatment (p < 0.001).
  
  
  CONCLUSIONS
  Retreatment criteria according to the PrONTO scheme showed good morphological and functional results in the patients with recurrent neovascular AMD treated but seemed to be defined too broadly for everyday clinical use with an irreversible loss under those conditions in cases of a recurrent episode. Accordingly, the latest recurrence criteria of the DOG/BVA/DOC recommendations should be applied.
authors.affiliation: Augenklinik, Ludwig-Maximilians-Universität, Klinikum der Universität München Campus Innenstadt, Mathildenstr. 8, 80336, München, Deutschland. Armin.Wolf@med.uni-muenchen.de
authors.forename: A
authors.initials: A
authors.lastname: Wolf
authors.forename: L
authors.initials: L
authors.lastname: Reznicek
authors.forename: J
authors.initials: J
authors.lastname: Muhr
authors.forename: M
authors.initials: M
authors.lastname: Ulbig
authors.forename: A
authors.initials: A
authors.lastname: Kampik
authors.forename: C
authors.initials: C
authors.lastname: Haritoglou
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab; D012189:Retrospective Studies; D055502:Secondary Prevention; D016896:Treatment Outcome; D014786:Vision Disorders / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D014792:Visual Acuity / Q000187:drug effects*; D057135:Wet Macular Degeneration / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab